Trametinib in Patients With NF1- , GNAQ- , or GNA11 -Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2.

MLA

Wisinski, Kari B., et al. “Trametinib in Patients With NF1- , GNAQ- , or GNA11 -Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2.” JCO Precision Oncology, vol. 7, Apr. 2023, p. e2200421. EBSCOhost, https://doi.org/10.1200/PO.22.00421.

APA

Wisinski, K. B., Flamand, Y., Wilson, M. A., Luke, J. J., Tawbi, H. A., Hong, F., Mitchell, E. P., Zwiebel, J. A., Chen, H., Gray, R. J., Li, S., McShane, L. M., Rubinstein, L. V., Patton, D., Williams, P. M., Hamilton, S. R., Behrens, R. J., Pennington, K. P., Conley, B. A., … Flaherty, K. T. (2023). Trametinib in Patients With NF1- , GNAQ- , or GNA11 -Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2. JCO Precision Oncology, 7, e2200421. https://doi.org/10.1200/PO.22.00421

Chicago

Wisinski, Kari B, Yael Flamand, Melissa A Wilson, Jason J Luke, Hussein A Tawbi, Fangxin Hong, Edith P Mitchell, et al. 2023. “Trametinib in Patients With NF1- , GNAQ- , or GNA11 -Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2.” JCO Precision Oncology 7 (April): e2200421. doi:10.1200/PO.22.00421.